Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight

Detailed results from Lilly 's first phase 3 trial in obesity or overweight presented at the American Diabetes Association's ®  82 nd Scientific Sessions ®  and simultaneously published in NEJM INDIANAPOLIS , June 4, 2022 /PRNewswire/ -- Detailed results from Eli Lilly and Company's (NYSE: LLY)